Metis TechBio debuted on the main board of the HKEX on 13 May under the Chapter 18C listing regime for specialist technology companies, raising around HKD2.1 billion in the world’s first listing of an AI?driven nano-delivery platform company.
Davis Polk, Han Kun Law Offices, 翱’惭别濒惫别苍测 and Commerce & Finance Law Offices advised on the transaction.
The IPO attracted a strong line?up of 18 cornerstone investors, including BlackRock, UBS Asset Management, China Venture Capital Innovation Investment Fund, Mirae Asset, Hillhouse?affiliated HHLRA, ORIX Asia, Deerfield and Fullgoal Fund.
Davis Polk acted as Hong Kong and US counsel to Metis TechBio, with global partners He Li, Jason Xu and Steve Wang leading the team. Senior counsel Sheen Xu and Wendy Kan provided support. Han Kun served as PRC counsel.
Jefferies, Deutsche Securities and CITIC Securities acted as joint sponsors. 翱’惭别濒惫别苍测 advised the sponsors on Hong Kong and US law, with partners Geng Ke, Zhu Ke and Vincent Wang leading the team. Commerce & Finance advised on PRC law, with partners Wang Bo, Zhang Meng and Chen Rui on the team.
Metis TechBio’s core technological strength lies in NanoForge, the world’s first self?developed AI?driven nano-delivery platform. Built on this foundation, the biotechnology company has developed three solution platforms: AiTEM, AiLNP and AiRNA. Among them, AiTEM significantly optimises formulation design for small?molecule drugs, reducing preclinical formulation development timelines from one to two years to less than three months.
The company is currently pre?commercial. In its prospectus, Metis TechBio stated that following the establishment of a partnership with a leading global pharmaceutical company, it became “commercial ready” from the third quarter of 2025.
Proceeds from the offering will be used for core research, development and advancement of its AI infrastructure and AI?enabled nanomaterials platform, ongoing and planned clinical trials, animal health and anti?ageing solutions, global expansion initiatives, working capital, and general corporate purposes.
